Keywords: Roche, RoActemra, Systemic JIA, UK, NICE

Draft guidance from UK’s NICE recommends Roche’s RoActemra for systemic JIA

Article | 27 October 2011

In final draft guidance published today, by the UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in